Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:35:52.733Z.
Calculation as of: 2026-10-06T16:35:52.733Z.
Quote observation: 2026-10-06T16:33:58.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8e18e4937bb179ad65bb801f5f057f36d78bd2e4af2c39ec5cecdad017acf428
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BriaCell Therapeutics Corp. (BCTX) | $35.10M | N/A | N/A | N/A | N/A |
| Elutia Inc (ELUT)vs › | $35.15M | 0.85 | 1.13 | 1.13 | 1.13 |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.50M | N/A | N/A | N/A | N/A |
| Accuray Incorporated (ARAY)vs › | $34.02M | N/A | 241.49 | 241.49 | 115.68 |
| DocGo Inc. (DCGO)vs › | $35.92M | N/A | 14.70 | 37.22 | 37.36 |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.42M | N/A | N/A | N/A | N/A |
| QT Imaging Holdings, Inc. (QTI)vs › | $36.76M | N/A | N/A | N/A | N/A |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.23M | N/A | N/A | N/A | N/A |
| EUDA Health Holdings Limited (EUDA)vs › | $32.76M | N/A | N/A | N/A | N/A |
| Edesa Biotech, Inc. (EDSA)vs › | $37.33M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
